<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03029169</url>
  </required_header>
  <id_info>
    <org_study_id>1691/16 S-IV</org_study_id>
    <nct_id>NCT03029169</nct_id>
  </id_info>
  <brief_title>Propafenone Versus Amiodarone in Septic Shock</brief_title>
  <acronym>PRASE</acronym>
  <official_title>Prospective Randomized Study of Efficacy and Safety of 1c Class Antiarrhythmic Agent (Propafenone) in Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charles University, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charles University, Czech Republic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Arrhythmias accompany septic shock in increased rates than in other ICU cohorts and their
      presence and management are related to patientÂ´s prognosis. 1c class antiarrhythmics are
      seldom administered in intensive care due to a dose dependent toxicity published in case
      reports and unfavourable outcome reported in a few prospective trials done on cardiology
      patients. The papers on 1c class antiarrhythmics do not take into consideration a complex
      haemodynamic assessment using echocardiography. The authors have recently presented a
      retrospective study on SV arrhythmias in septic shock patients demonstrating favourable
      effect and safety of propafenone which showed higher antiarrhythmic efficacy than amiodarone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary aim is to verify the conclusions of the retrospective study, i.e. efficacy and safety
      of propafenone, in a prospective blinded randomized trial performed in two large intensive
      care units. Secondary aims are to monitor the electromechanics of left atrium in patients
      with SV arrhythmias in septic shock.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 23, 2017</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>Provided by a dedicated study nurse</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of propafenone</measure>
    <time_frame>1 year</time_frame>
    <description>cardioversion rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ICU mortality of septic shock patients on propafenone for a SV arrhythmia</measure>
    <time_frame>1 year</time_frame>
    <description>ICU mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>28-day mortality of septic shock patients on propafenone for a SV arrhythmia</measure>
    <time_frame>2 years</time_frame>
    <description>28-day mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12-month mortality of septic shock patients on propafenone for a SV arrhythmia</measure>
    <time_frame>2 years</time_frame>
    <description>12-month mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Electromechanics of left atrium</measure>
    <time_frame>1 year</time_frame>
    <description>left atrial emptying</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electromechanics of LA</measure>
    <time_frame>1 year</time_frame>
    <description>isovolumic and ejection times</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Supraventricular Arrhythmia</condition>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Propafenone i.v.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in septic shock with a new onset supraventricular arrhythmia are randomized either to arm treated with propafenone or with amiodarone. Both arms will have standard treatment, there are no limits to indicated electric cardioversion as part of treatment.
Intervention: Bolus of 35-70 mg intravenous propafenone followed by continuous infusion of 400-840 mg/24h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amiodarone i.v.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in septic shock with a new onset supraventricular arrhythmia are randomized either to arm treated with propafenone or with amiodarone. Both arms will have standard treatment, there are no limits to indicated electric cardioversion as part of treatment.
Intervention: Bolus of 150-300 mg of intravenous amiodarone followed by continuous infusion of 600-1800 mg/24h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propafenone i.v.</intervention_name>
    <description>Treatment</description>
    <arm_group_label>Propafenone i.v.</arm_group_label>
    <other_name>Antiarrhythmic therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone i.v.</intervention_name>
    <description>Treatment</description>
    <arm_group_label>Amiodarone i.v.</arm_group_label>
    <other_name>Antiarrhythmic therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Septic shock with a new onset SV arrhythmia

          -  LV systolic function normal to moderately reduced according to echocardiography.

        Exclusion Criteria:

          -  Severe LV systolic dysfunction

          -  More than 1st degree AV block

          -  High dose vasopressor therapy with continuous noradrenaline &gt; 1.0 ug/kg.min

          -  Known intolerance to amiodarone or propafenone

          -  Absence of septic shock

          -  Chronic AF

          -  Dependence on pacemaker

          -  Status after MAZE procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Balik, A/Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Anaesthesia and Intensive Care</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin Balik, A/Prof</last_name>
    <phone>+420224963366</phone>
    <email>martin.balik@vfn.cz</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dept of Anaesthesia and Intensive Care, General University Hospital, 1st Medical Faculty, Charles University</name>
      <address>
        <city>Prague 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Balik, A/Prof</last_name>
      <phone>+420224963366</phone>
      <email>martin.balik@vfn.cz</email>
    </contact>
    <investigator>
      <last_name>Martin Balik, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2016</study_first_submitted>
  <study_first_submitted_qc>January 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2017</study_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charles University, Czech Republic</investigator_affiliation>
    <investigator_full_name>Martin Balik</investigator_full_name>
    <investigator_title>A/Prof, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Supraventricular Arrhythmia</keyword>
  <keyword>Septic shock</keyword>
  <keyword>Propafenone</keyword>
  <keyword>Amiodarone</keyword>
  <keyword>Intensive Care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
    <mesh_term>Anti-Arrhythmia Agents</mesh_term>
    <mesh_term>Propafenone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

